Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 72 articles: HTML format

Single Articles

September 2021
1. ZHANG L, Wu ZY, Li J, Lin Y, et al
   Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
   Int J Cancer. 2021 Sep 30. doi: 10.1002/ijc.33830.
   PubMed     Abstract available
   
   
   
2. SARINK D, White KK, Loo LWM, Wu AH, et al
   Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the Multiethnic Cohort Study.
   Int J Cancer. 2021 Sep 6. doi: 10.1002/ijc.33795.
   PubMed     Abstract available
   
   
   
3. COLE SE, John EM, Hines LM, Phipps AI, et al
   Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
   Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33791.
   PubMed     Abstract available
   
   
   August 2021
4. MEEGDES M, Geurts SME, Erdkamp FLG, Dercksen MW, et al
   The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
   Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33785.
   PubMed     Abstract available
   
   
   
5. EVANS DG, van Veen EM, Byers H, Roberts E, et al
   The importance of Ethnicity: are breast cancer Polygenic Risk Scores ready for women who are not of white European origin?
   Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33782.
   PubMed     Abstract available
   
   
   
6. ZHENG KH, Zhu K, Wactawski-Wende J, Freudenheim JL, et al
   Caffeine Intake from Coffee and Tea and Invasive Breast Cancer Incidence among Postmenopausal Women in the Women's Health Initiative.
   Int J Cancer. 2021 Aug 21. doi: 10.1002/ijc.33771.
   PubMed     Abstract available
   
   
   
7. TANIGUCHI H, Natori Y, Miyagi Y, Hayashi K, et al
   Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
   Int J Cancer. 2021;149:646-656.
   PubMed     Abstract available
   
   
   July 2021
8. CYRUS K, Wang Q, Sharawi Z, Noguchi G, et al
   Role of calcium in hormone independent and resistant breast cancer.
   Int J Cancer. 2021 Jul 21. doi: 10.1002/ijc.33745.
   PubMed     Abstract available
   
   
   
9. KOSTOS L, Hong W, Lee B, Tran B, et al
   Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
   Int J Cancer. 2021;149:409-419.
   PubMed     Abstract available
   
   
   
10. JANSANA A, Poblador-Plou B, Gimeno-Miguel A, Lanzuela M, et al
    Multimorbidity clusters among long-term breast cancer survivors in Spain: Results of the SURBCAN Study.
    Int J Cancer. 2021 Jul 13. doi: 10.1002/ijc.33736.
    PubMed     Abstract available
    
    
    
11. ZHANG L, Zhou M, Liu Y, Du F, et al
    Is It Beneficial for Patients with pT1-2N1M0 Breast Cancer to Receive Post-Mastectomy Radiotherapy? An Analysis Based on RecurIndex Assay.
    Int J Cancer. 2021 Jul 5. doi: 10.1002/ijc.33730.
    PubMed     Abstract available
    
    
    
12. CHA C, Ahn SG, Kim D, Lee J, et al
    Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33726.
    PubMed     Abstract available
    
    
    
13. DARLIX A, Hirtz C, Mollevi C, Ginestet N, et al
    Serum GFAP is a predictor of brain metastases in patients with metastatic breast cancer.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33724.
    PubMed     Abstract available
    
    
    June 2021
14. BUDUKH A, Dikshit R, Chaturvedi P
    Outcome of the randomized control screening trials on Oral, Cervix and Breast Cancer from India and way forward in COVID-19 pandemic situation.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33712.
    PubMed    
    
    
    
15. ISHEDEN G, Grassmann F, Czene K, Humphreys K, et al
    Lymph node metastases in breast cancer: investigating associations with tumor characteristics, molecular subtypes, and polygenic risk score using a continuous growth model.
    Int J Cancer. 2021 Jun 7. doi: 10.1002/ijc.33704.
    PubMed     Abstract available
    
    
    May 2021
16. HAGENAARS SC, de Groot S, Cohen D, Dekker TJA, et al
    Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
    Int J Cancer. 2021 May 27. doi: 10.1002/ijc.33700.
    PubMed     Abstract available
    
    
    
17. ALSENDI M, O'Reilly D, Zeidan YH, Kelly CM, et al
    Oligometastatic Breast Cancer: Are We There Yet?
    Int J Cancer. 2021 May 20. doi: 10.1002/ijc.33693.
    PubMed     Abstract available
    
    
    
18. WU AH, Franke AA, Wilkens LR, Tseng C, et al
    Risk of Breast Cancer and pre-diagnostic urinary excretion of bisphenol A, triclosan, and parabens: the Multiethnic Cohort Study.
    Int J Cancer. 2021 May 20. doi: 10.1002/ijc.33692.
    PubMed     Abstract available
    
    
    
19. LILLEBORGE M, Falk RS, Sorlie T, Ursin G, et al
    Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33680.
    PubMed     Abstract available
    
    
    April 2021
20. JEONG H, Jeong JH, Kim JE, Ahn JH, et al
    Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer.
    Int J Cancer. 2021 Apr 27. doi: 10.1002/ijc.33613.
    PubMed     Abstract available
    
    
    
21. BRANE A, Behring M, Halilova KI, Norian L, et al
    Comments on "Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns".
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33605.
    PubMed    
    
    
    
22. KATUWAL S, Jousilahti P, Pukkala E
    Causes of death among women with breast cancer: A follow-up study of 50,481 women with breast cancer in Finland.
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33607.
    PubMed     Abstract available
    
    
    
23. BULLIARD JL, Beau AB, Njorv S, Wu WY, et al
    Breast cancer screening and overdiagnosis.
    Int J Cancer. 2021 Apr 19. doi: 10.1002/ijc.33602.
    PubMed     Abstract available
    
    
    
24. KHAN SA, Hernandez-Villafuerte KV, Muchadeyi MT, Schlander M, et al
    Cost-effectiveness of risk-based breast cancer screening: A systematic review.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33593.
    PubMed     Abstract available
    
    
    
25. TANG SC, Capra CL, Ajebo GH, Meza-Junco J, et al
    Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33597.
    PubMed     Abstract available
    
    
    
26. CHRISTAKOUDI S, Pagoni P, Ferrari P, Cross AJ, et al
    Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer. 2021;148:1637-1651.
    PubMed     Abstract available
    
    
    March 2021
27. PARK YM, Shivappa N, Petimar J, Hodgson ME, et al
    Dietary inflammatory potential, oxidative balance score, and risk of breast cancer: findings from the Sister Study.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33581.
    PubMed     Abstract available
    
    
    
28. INDUKURI R, Jafferali MH, Song D, Damdimopoulos A, et al
    Genome-Wide Estrogen Receptor beta Chromatin Binding in Human Colon Cancer Cells Reveals its Tumor Suppressor Activity.
    Int J Cancer. 2021 Mar 22. doi: 10.1002/ijc.33573.
    PubMed     Abstract available
    
    
    
29. KOCH T, Jorgensen JT, Christensen J, Dehlendorff C, et al
    Breast Cancer Rate after Oophorectomy: A Prospective Danish Cohort Study.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33563.
    PubMed     Abstract available
    
    
    
30. SONNENBLICK A, Agbor-Tarh D, de Azambuja E, Hultsch S, et al
    STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.
    Int J Cancer. 2021;148:1529-1535.
    PubMed     Abstract available
    
    
    
31. LOFTUS PG, Watson L, Deedigan LM, Camarillo-Retamosa E, et al
    Targeting stromal cell Syndecan-2 reduces breast tumour growth, metastasis and limits immune evasion.
    Int J Cancer. 2021;148:1245-1259.
    PubMed     Abstract available
    
    
    February 2021
32. BELTJENS F, Molly D, Bertaut A, Richard C, et al
    ER-/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33539.
    PubMed     Abstract available
    
    
    
33. KIM N, Chang JS, Shah C, Shin H, et al
    Hypofractionated volumetric-modulated arc therapy for breast cancer: A propensity-score-weighted comparison of radiation-related toxicity.
    Int J Cancer. 2021 Feb 18. doi: 10.1002/ijc.33525.
    PubMed     Abstract available
    
    
    
34. TRAN QH, Than VT, Luu PL, Clarke D, et al
    A Novel Signature Predicts Recurrence Risk and Therapeutic Response in Breast Cancer Patients.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33512.
    PubMed     Abstract available
    
    
    
35. ARTHUR RS, Dannenberg AJ, Rohan TE
    The association of prediagnostic circulating levels of cardiometabolic markers, testosterone and SHBG with risk of breast cancer among normal weight postmenopausal women in the UK Biobank.
    Int J Cancer. 2021 Feb 10. doi: 10.1002/ijc.33508.
    PubMed     Abstract available
    
    
    
36. ELGHAZALY H, Aref AT, Anderson BO, Arun B, et al
    The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low- and middle-income countries and the MENA Region.
    Int J Cancer. 2021 Feb 9. doi: 10.1002/ijc.33506.
    PubMed     Abstract available
    
    
    
37. WATT GP, John EM, Bandera EV, Malone KE, et al
    Race, Ethnicity and Risk of Second Primary Contralateral Breast Cancer in the United States.
    Int J Cancer. 2021 Feb 5. doi: 10.1002/ijc.33501.
    PubMed     Abstract available
    
    
    
38. GRAESER M, Schrading S, Gluz O, Strobel K, et al
    Early Response by MR Imaging and Ultrasound as Predictor of Pathologic Complete Response to 12-Week Neoadjuvant Therapy for Different Early Breast Cancer Subtypes: Combined Analysis from the WSG ADAPT Subtrials.
    Int J Cancer. 2021 Feb 3. doi: 10.1002/ijc.33495.
    PubMed     Abstract available
    
    
    
39. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available
    
    
    January 2021
40. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
    First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
    PubMed     Abstract available
    
    
    
41. TENG NM, Price CA, McKee AM, Hall LJ, et al
    Exploring the impact of gut microbiota and diet on Breast Cancer risk and progression.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33496.
    PubMed     Abstract available
    
    
    
42. OLASEHINDE O, Alatise O, Omisore A, Wuraola F, et al
    Contemporary management of breast cancer in Nigeria: insights from an institutional database.
    Int J Cancer. 2021 Jan 27. doi: 10.1002/ijc.33484.
    PubMed     Abstract available
    
    
    
43. IWASE M, Matsuo K, Koyanagi YN, Ito H, et al
    Alcohol consumption and breast cancer risk in Japan: a pooled analysis of eight population-based cohort studies.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33478.
    PubMed     Abstract available
    
    
    
44. BYRD DA, Vogtmann E, Wu Z, Han Y, et al
    Associations of fecal microbial profiles with breast cancer and non-malignant breast disease in the Ghana Breast Health Study.
    Int J Cancer. 2021 Jan 18. doi: 10.1002/ijc.33473.
    PubMed     Abstract available
    
    
    
45. PAN JW, Zabidi MMA, Chong BK, Meng MY, et al
    Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.
    Int J Cancer. 2021 Jan 7. doi: 10.1002/ijc.33463.
    PubMed     Abstract available
    
    
    
46. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    PubMed     Abstract available
    
    
    
47. LAMEIJER JRC, Nederend J, Voogd AC, Tjan-Heijnen VCG, et al
    Frequency and diagnostic outcome of bilateral recall at screening mammography.
    Int J Cancer. 2021;148:48-56.
    PubMed     Abstract available
    
    
    December 2020
48. LONJOU C, Eon-Marchais S, Truong T, Dondon MG, et al
    Gene and pathway level analyses of iCOGS variants highlight novel signalling pathways underlying familial breast cancer susceptibility.
    Int J Cancer. 2020 Dec 24. doi: 10.1002/ijc.33457.
    PubMed     Abstract available
    
    
    
49. MITRA D, Vega-Rubin-de-Celis S, Royla N, Bernhardt S, et al
    Abrogating GPT2 in triple negative breast cancer inhibits tumor growth and promotes autophagy.
    Int J Cancer. 2020 Dec 24. doi: 10.1002/ijc.33456.
    PubMed     Abstract available
    
    
    
50. KIM S, Park B
    Association between changes in mammographic density category and the risk of breast cancer: A nationwide cohort study in East-Asian women.
    Int J Cancer. 2020 Dec 23. doi: 10.1002/ijc.33455.
    PubMed     Abstract available
    
    
    
51. MUPPALA S, Xiao R, Gajeton J, Krukovets I, et al
    Thrombospondin-4 mediates hyperglycemia- and TGF-beta-induced inflammation in breast cancer.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33439.
    PubMed     Abstract available
    
    
    November 2020
52. VAN DER MEER DJ, Kramer I, van Maaren MC, van Diest PJ, et al
    Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989-2017.
    Int J Cancer. 2020 Nov 30. doi: 10.1002/ijc.33417.
    PubMed     Abstract available
    
    
    
53. WHITE AJ, Gregoire AM, Taylor KW, Eberle C, et al
    Adolescent use of hair dyes, straighteners and perms in relation to breast cancer risk.
    Int J Cancer. 2020 Nov 30. doi: 10.1002/ijc.33413.
    PubMed     Abstract available
    
    
    
54. TOGAWA K, Anderson BO, Foerster M, Galukande M, et al
    Geospatial barriers to health care access for breast cancer diagnosis in sub-Saharan African settings: the African Breast Cancer - Disparities in Outcomes (ABC-DO) Cohort Study.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33400.
    PubMed     Abstract available
    
    
    
55. NGUYEN TL, Schmidt DF, Makalic E, Maskarinec G, et al
    Novel mammogram-based measures improve breast cancer risk prediction beyond an established mammographic density measure.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33396.
    PubMed     Abstract available
    
    
    
56. AYENI OA, Norris SA, Joffe M, Cubasch H, et al
    Pre-existing morbidity profile of women newly diagnosed with breast cancer in sub-Saharan Africa: African Breast Cancer-Disparities in Outcomes (ABC-DO) study.
    Int J Cancer. 2020 Nov 12. doi: 10.1002/ijc.33387.
    PubMed     Abstract available
    
    
    
57. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    PubMed     Abstract available
    
    
    October 2020
58. SATAGOPAN JM, Stroup A, Kinney AY, Dharamdasani T, et al
    Breast cancer among Asian Indian and Pakistani Americans: A surveillance, epidemiology and end results-based study.
    Int J Cancer. 2020 Oct 25. doi: 10.1002/ijc.33331.
    PubMed     Abstract available
    
    
    
59. ZUPUNSKI L, Yaumenenka A, Ryzhov A, Veyalkin I, et al
    Breast cancer incidence in the regions of Belarus and Ukraine most contaminated by the Chernobyl accident: 1978-2016.
    Int J Cancer. 2020 Oct 16. doi: 10.1002/ijc.33346.
    PubMed     Abstract available
    
    
    
60. ZHANG Y, Wang P, Li X, Ning S, et al
    GABC: A Comprehensive Resource and Genome Atlas for Breast Cancer.
    Int J Cancer. 2020 Oct 16. doi: 10.1002/ijc.33347.
    PubMed     Abstract available
    
    
    
61. YUAN S, Kar S, Vithayathil M, Carter P, et al
    Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two-sample Mendelian randomization study.
    Int J Cancer. 2020;147:1895-1903.
    PubMed     Abstract available
    
    
    September 2020
62. KINLEN LJ, Gilham C, Ray R, Thomas DB, et al
    Cohabitation, infection and breast cancer risk.
    Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33319.
    PubMed     Abstract available
    
    
    
63. WEITZER J, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al
    Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain Study).
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33310.
    PubMed     Abstract available
    
    
    
64. TAN PS, Alsheh Ali M, Eriksson M, Hall P, et al
    Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics - a population-based cohort study.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33309.
    PubMed     Abstract available
    
    
    
65. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed     Abstract available
    
    
    
66. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    PubMed     Abstract available
    
    
    August 2020
67. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available
    
    
    
68. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available
    
    
    July 2020
69. AKCAY IM, Celik E, Agaoglu NB, Alkurt G, et al
    Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
    Int J Cancer. 2020 Jul 13. doi: 10.1002/ijc.33199.
    PubMed     Abstract available
    
    
    
70. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available
    
    
    November 2019
71. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available
    
    
    August 2019
72. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: